Shenzhen Airlines Launches Direct Flight From Shenzhen to Barcelona Successfully
The flight ZH9065 with 203 passengers on board, which took off from Shenzhen of China, landed in Barcelona of Spain in the morning on August 28, marked the new direct flight has been launched successfully by Shenzhen Airlines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828849009/en/
Zhou Zhiwei(L6), board member and executive vice president of Shenzhen Airlines, and Hu Aimin(L5), the deputy consul-general of China in Barcelona, welcome the cabin crew and passengers of the debut flight of Shenzhen-Barcelona route in Barcelona on August 28. (Photo: Business Wire)
Together with the Barcelona municipality, the general consulate of China in Barcelona, the Air Routes Development Committee in Barcelona (CDRA), Network of airports in Spain (AENA), the Shenzhen airlines and its partner Air China, organized a warm ceremony to welcome the passengers, while the major of Barcelona, the deputy consul-general of China in Barcelona, and dozens of representatives of those organizers attended the event.
The round flight connecting Shenzhen and Barcelona is operated by Shenzhen Airlines twice a week, on every Monday and Friday. Flight ZH9066 from Barcelona to Shenzhen departs at 11:30 local time and arrives at 07:00 Beijing time, the return flight ZH9065 departs at 11:30 and arrives at 08:05.
The advanced Airbus A330 wide-body passenger aircraft has been invested in this new route, which brings every people a comfortable journey.
In addition, passengers taking this flight are provided with cross-city transfers, free transit hotels, express visa process, and other exclusive services.
Shenzhen Airlines was established in 1992 in Shenzhen, one of the core cities of the Guangdong-Hong Kong-Macao Greater Bay Area in China. With 226 passenger aircraft of various types, the fleet of Shenzhen Airlines ranks the fifth in China. Supporting by 15 branches or bases across the whole country, Shenzhen Airlines operates now more than 200 routes, covering the major destinations in China and abroad.
Shenzhen is one of the five major airports in China, also an important transportation hub in the Asia-Pacific region, plays an important role for connecting China and the other countries.
2023 marks the 50th anniversary of the establishment of diplomatic relations between Spain and China, and the second anniversary of Barcelona and Shenzhen becoming sister cities. The new route sets up a convenient air bridge between the two cities, which will further promote the cooperation between the two places and even between the two nations in the fields of sci-tech, culture, tourism, and trade.
The new route is Shenzhen Airlines' second direct flight from Europe following the first one between London and Shenzhen. Shenzhen Airlines will continue to enrich the route network in near future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828849009/en/
Contact information
Z. Pan info@xinhuaeurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom